BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,046 filers reported holding BAXTER INTL INC in Q4 2017. The put-call ratio across all filers is 0.57 and the average weighting 0.3%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $127,482 | +2.0% | 3,143 | +28.2% | 0.01% | -12.5% |
| Q4 2022 | $124,958 | +10.6% | 2,451 | +17.3% | 0.01% | 0.0% |
| Q3 2022 | $113,000 | -55.9% | 2,090 | -33.5% | 0.01% | -84.0% |
| Q1 2019 | $256,000 | +36.9% | 3,143 | +10.6% | 0.05% | +6.4% |
| Q4 2018 | $187,000 | -17.6% | 2,843 | -3.4% | 0.05% | +30.6% |
| Q3 2018 | $227,000 | +4.6% | 2,942 | -0.1% | 0.04% | -41.0% |
| Q2 2018 | $217,000 | +2.4% | 2,944 | -10.3% | 0.06% | +32.6% |
| Q4 2017 | $212,000 | -7.4% | 3,283 | -10.1% | 0.05% | -14.8% |
| Q3 2017 | $229,000 | – | 3,653 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Soditic Asset Management LLP | 147,620 | $7,951,000 | 9.91% |
| NUANCE INVESTMENTS, LLC | 5,429,702 | $292,444,000 | 6.51% |
| Endurant Capital Management LP | 245,093 | $13,201,000 | 4.30% |
| Veritas Asset Management LLP | 8,589,401 | $462,625,000 | 3.83% |
| GENERATION INVESTMENT MANAGEMENT LLP | 11,876,040 | $639,644,000 | 3.80% |
| Sivik Global Healthcare LLC | 120,000 | $6,463,000 | 3.59% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 480,500 | $25,880,000 | 3.31% |
| Integral Health Asset Management, LLC | 300,000 | $16,158,000 | 3.14% |
| Boothe Investment Group, Inc. | 89,078 | $4,798,000 | 3.11% |
| Glenview Capital Management | 2,257,019 | $121,563,000 | 3.04% |